Skip to main content
OpenTrials
Completed

NCT Number: NCT05918497

Comparison Between Variable Time Regimen of Dosing L-Thyroxine for Treatment Hypothyroid Fasting Ramadan

This is a study aiming to report the effect of a variable time regimen of L T4 during Ramadan, as an easier alternative, on adherence and thyroid status after Ramadan compared to standard daily dosing.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag Faculty of Medicine

Sohag, Egypt

About this study

Patient and Method This a prospective study will be including Muslim hypothyroid patients willing to fast Ramadan during the year 2023 attending outpatient clinic, Sohag faculty of medicine, Sohag university, Egypt.

All included patients will be euthyroid, and stable on the same L T4 dose for at least 3 months before the start of Ramadan.

Exclusion criteria

will be thyroid cancer patients requiring suppressive therapy, central hypothyroidism, pregnancy, coronary heart disease, arrythmia, chronic heart failure, liver cirrhosis, renal failure, acute medical, or surgical illness at the time of evaluation to avoid acute and chronic non thyroidal illness syndromes.

the patients will be divided into three groups. Group 1 patients who will switch to twice weekly dosing. Their weekly dose was divided equally into those doses, given at successive fixed days of the week. Group 2 patients who will switch to once weekly dosing. Group 3 patients who will continue to take L T4 on standard daily basis.

Patients from are free to follow one of four L T4 regimens during Ramadan, regimen 1: to take L T4 60 min before Iftar and beverages, regimen 2: to take L T4 3-4 h after Iftar, 60 min before Suhor meal, regimen 3: to take L T4 before the start of next fast 3 4 h after an early Suhor at midnight. If patients mixed between regimens 1 and 2, this was labeled regimen 4.

Adherence will assess by interviewing participants during post Ramadan visit. Nonadherence define as stopping food and beverages for less than 3 h before L T4 tablet(s) or stopping food and beverages for less than 45 min after L T4 tablet(s). Patients who skipped L T4 treatment for 2 or more days without making up for their missed doses will be excluded from the study.

Thyroid status will reassess in post Ramadan visit using TSH, provided that this visit comes within 6 weeks from the end of Ramadan.

Ethical aspect Informed written consent will be taken from all patients to include their data in the study. The research will be approved by medical ethics committee of Sohag University Faculty of Medicine Statistical analysis Data will be analyzed using STATA version 14.2 (Statistical Software: Release 14.2 College Station, TX: Stata Corp LP). Quantitative data will be represented as mean, standard deviation, median and range. normally distributed. Qualitative data will be presented as numbers and percentages. Chi square test will be used for comparison of percentages in different groups. P value will be considered significant if it was less than 0.05.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All included patients will be euthyroid, and stable on the same L T4 dose for at least 3 months before the start of Ramadan.

Exclusion criteria

  • Exclusion criteria will be thyroid cancer patients requiring suppressive therapy, central hypothyroidism, pregnancy, coronary heart disease, arrythmia, chronic heart failure, liver cirrhosis, renal failure, acute medical, or surgical illness at the time of evaluation to avoid acute and chronic non thyroidal illness syndromes.

Treatment and study plan

Primary outcomes

  1. Comparison Between Variable Time Regimen of Dosing L-Thyroxine for Treatment Hypothyroid Fasting Ramadan

    Time frame: 2 months after ramadan

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Jun 26, 2023
Registry last updated
Aug 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.